Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

• Status: Unknown status
• Trial end date: 2013-12-01

Summary

The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Center, Korea
• Collaborators: Asan Medical Center; Severance Hospital
• Treatments: Cytarabine; Etoposide; Etoposide phosphate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Oxaliplatin; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate